Leroy Pacheco, MD
Rheumatology · Albuquerque, NMNPI 1568438752
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,077 of the $8,376 with a category attached, or 72.6%. It is spread thinly across 28 manufacturers, the largest accounting for just 23.7%.
Across 336 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB Biosciences Inc.$2K
- Amgen$1K
- AbbVie$956
- UCB, Inc.$788
- Johnson & Johnson$640
- AstraZeneca$512
- plus $2K from 22 others
Across 220 payments — averaging $11,113 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$1.1M
- Eli Lilly$432K
- AbbVie$293K
- Janssen Research & Development, LLC$199K
- Novartis$122K
- Biogen$87K
- plus $246K from 10 others
What the payments were for
- Travel & lodging$1,70120%
- Food & beverage$6,07773%
- Education$5987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB Biosciences Inc. | 9 | $1,986 |
| Amgen(2 entities) | 39 | $1,045 |
| AbbVie | 70 | $956 |
| UCB, Inc. | 32 | $788 |
| Johnson & Johnson | 31 | $640 |
| AstraZeneca(2 entities) | 28 | $512 |
| Genentech USA, Inc. | 31 | $327 |
| Sobi, Inc | 9 | $245 |
| Novartis | 13 | $229 |
| Sanofi-aventis U.S. LLC | 4 | $201 |
| E.r. Squibb & Sons, L.L.C. | 10 | $199 |
| Lilly USA, LLC | 9 | $176 |
| GSK | 8 | $167 |
| Boehringer Ingelheim | 8 | $166 |
| Pfizer | 9 | $154 |
| Organon | 4 | $113 |
| Gilead | 4 | $87 |
| Aurinia Pharma U.S., Inc. | 4 | $84 |
| Sanofi | 3 | $72 |
| Kyowa Kirin, Inc. | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $31 |
| Pacira Therapeutics, Inc. | 1 | $24 |
| Bristol Myers Squibb | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $20 |
| Pacira Pharmaceuticals Incorporated | 1 | $20 |
| Merck | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $13 |
How this compares
$8,376 in reported general payments places this provider in the 85th percentile of 44 rheumatology providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EnbrelEtanercept | 72 | $668,416 |
| Enbrel SureclickEtanercept | 74 | $639,336 |
| Humira(Cf) PenAdalimumab | 67 | $578,774 |
| Orencia ClickjectAbatacept | 69 | $448,695 |
| Humira PenAdalimumab | 49 | $413,549 |
| Xeljanz XrTofacitinib Citrate | 21 | $159,789 |
| Actemra ActpenTocilizumab | 28 | $143,302 |
| BenlystaBelimumab | 30 | $141,384 |
| RinvoqUpadacitinib | 18 | $119,134 |
| Taltz AutoinjectorIxekizumab | 13 | $90,781 |
| ActemraTocilizumab | 14 | $64,883 |
| Amjevita(Cf) AutoinjectorAdalimumab-Atto | 19 | $37,189 |
| OxycontinOxycodone Hcl | 23 | $28,671 |
| MethotrexateMethotrexate Sodium | 688 | $16,198 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 414 | $15,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenEnbrel | $1,045 | $668,41672 claims |
| GSKBenlysta | $167 | $141,38430 claims |
| AbbVieRinvoq | $956 | $119,13418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 44 rheumatology providers in New Mexico.
Other rheumatology in Albuquerque
- Wilmer SibbittAlbuquerque$9K
- Albert RizzoliAlbuquerque$7K
- Scott StoernerAlbuquerque$5K
- Andres PeisajovichAlbuquerque$4K
- Sabeen YaqubAlbuquerque$4K
- Mirza BegAlbuquerque$4K
- Ahsan IqbalAlbuquerque$3K
- Peter RosandichAlbuquerque$2K
- Juliet CoquiaAlbuquerque$2K
- Jacqueline DeanAlbuquerque$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.